nab-Paclitaxel ( nab-P ) is approved , in the United States , in combination with carboplatin for the first-line treatment of advanced non-small-cell lung cancer , based on a randomized phase 3 trial of nab-P plus carboplatin ( nab-P/C ) versus solvent-based paclitaxel plus carboplatin ( sb-P/C ) .